A Johnson & Johnson drug acquired as part of a $6.5 billion deal has preliminary data showing it met the main goal of a mid-stage test in a rare blood disorder that can become fatal to fetuses. Full data from the trial will be presented at a future scientific meeting.
Johnson & Johnson is stopping clinical development of an experimental HIV vaccine after the four-shot regimen did not beat a placebo in a late-stage study. The clinical trial failure comes follows the 2021 failure of the vaccine candidate in a different study population.
When it comes to managing inbound phone calls, underperformance has devastating cost implications.
A panel of healthcare data experts recently broke down some of healthcare’s most common buzzwords at HLTH. While the experts agreed that many industry professionals still struggle to grasp the true denotations of words and phrases like “interoperability” and “reimagining healthcare,” the panelists said these terms can be quite meaningful once they’re unpacked.
The team behind the World Without Disease Accelerator, part of Janssen Research & Development, one of the Janssen Pharmaceutical companies of Johnson & Johnson, is embracing an ambitious paradigm focused on disease prevention, interception and cure.
Verily and Janssen say studying Covid-19 immune responses could yield data that helps clinicians treat the disease. They add that the research could also apply to other illnesses caused by respiratory pathogens.
Data analytics startup Verana Health struck a partnership with Janssen Research & Development. They’ll focus on exploring better treatments for diabetic retinopathy and macular edema.
The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.
The deal will focus in particular on developing an NGS-based companion diagnostic to aid enrollment in clinical trials, especially for non-small cell lung cancer. Thermo Fisher signed a similar deal with Eli Lilly in September.
The French drugmaker said the agency had accepted its application for isatuximab, a potential competitor to J&J's Darzalex. Positive Phase III data for isatuximab were presented at the ASCO meeting last month.
The company, whose FDA-approved products include the myeloma drug Darzalex and the chronic leukemia drug Arzerra, hopes to launch its own proprietary product by 2025.
The drug was approved along with a companion diagnostic to detect alterations in FGFR2 and FGFR3. The drug is approved for patients with locally advanced or metastatic UC who carry those mutations.
Join us on February 26 at 3 pm ET, and we’ll dive into the key areas where practices are losing time and money and provide solutions to overcome them.
The drug, a reformulation of ketamine, was approved for patients who have failed on other antidepressants. The original form of ketamine, approved as an anesthetic, has long been explored as a treatment for depression.
The Senate Finance Committee grilled executives from seven of the biggest drugmakers about the dramatic rise in drug costs.
While zanubrutinib showed a higher response rate in the same mantle cell lymphoma setting for which Imbruvica is approved, the Phase II study enrolled younger, less heavily pretreated patients than those in Imbruvica's pivotal trial.
The company currently has a product candidate in the late-discovery phase, an EGFR-targeting drug for lung cancer that would go after a resistance mechanism against existing kinase inhibitors.
Bispecific antibodies like Amgen's AMG 420 could present some competition to CAR-Ts. But could sequential use of the therapies - which target the same antigen - be possible?